Рет қаралды 182
In this interview, Dr. Michael Walsh discusses the PEXIVAS trial that has changed the paradigm regarding how nephrologists manage ANCA associated vasculitis.
He discusses the new steroid taper protocol to minimize steroid related adverse effects, his thoughts on plasma exchange, as well as other exciting developments on the horizon.
Visit us 👇
www.glomcon.org
my.glomcon.org